Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias
Dosil Garcia, Maria Alba
Mirantes Barbeito, Cristina
Navaridas Fernández de Bobadilla, Raúl
Gatius Calderó, Sònia
Santacana Espasa, Maria
Moiola, Cristian P.
Dolcet Roca, Xavier
MetadataShow full item record
PTEN is one of the most frequently mutated genes in human cancers. The frequency of PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to dysregulation of cell division, and promotes the accumulation of cell cycle complexes such as cyclin D1-CDK4/6, which is an important feature of the tumour phenotype. Cell cycle proteins have been presented as key targets in the treatment of the pathogenesis of cancer, and several CDK inhibitors have been developed as a strategy to generate new anticancer drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole. Here, we used a tamoxifen-inducible Pten knockout mouse model to assess the antitumour effects of cyclin D1 knockout and CDK4/6 inhibition by palbociclib on endometrial tumours. Interestingly, both cyclin D1 deficiency and palbociclib treatment triggered shrinkage of endometrial neoplasias. In addition, palbociclib treatment significantly increased the survival of Pten-deficient mice, and, as expected, had a general effect in reducing tumour cell proliferation. To further analyse the effects of palbociclib on endometrial carcinoma, we established subcutaneous tumours with human endometrial cancer cell lines and primary endometrial cancer xenografts, which allowed us to provide more translational and predictive data. To date, this is the first preclinical study evaluating the response to CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, and it reveals an important role of cyclin D-CDK4/6 activity in their development.
Is part ofJournal of Pathology, 2017, vol. 242, núm. 2, p. 152-164
European research projects
Showing items related by title, author, creator and subject.
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels Llobet Navàs, David; Eritja Sánchez, Núria; Domingo, Mónica; Bergadà Bertran, Laura; Mirantes Barbeito, Cristina; Santacana Espasa, Maria; Pallares, Judit; Macià Armengol, Anna; Yeramian Hakim, Andree; Encinas Martín, Mario; Moreno-Bueno, Gema; Palacios, José; Lewis, Robert E.; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Elsevier Inc, 2011)The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway participates in many processes altered in development and progression of cancer in human beings such as proliferation, transformation, differentiation, and ...
A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium Eritja Sánchez, Núria; Felip, Isidre; Dosil Garcia, Maria Alba; Vigezzi, Lucia; Mirantes Barbeito, Cristina; Yeramian Hakim, Andree; Navaridas Fernández de Bobadilla, Raúl; Santacana Espasa, Maria; Llobet Navàs, David; Yoshimura, Akihiko; Nomura, Masatoshi; Encinas Martín, Mario; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Nature Publishing Group, 2017-05-19)The TGF-β/Smad and the PI3K/AKT signaling pathways are important regulators of proliferation and apoptosis, and their alterations lead to cancer development. TGF-β acts as a tumor suppressor in premalignant cells, but it ...
An inducible knockout mouse to model the cellautonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias Mirantes Barbeito, Cristina; Eritja Sánchez, Núria; Dosil, Maria Alba; Santacana Espasa, Maria; Pallares, Judit; Gatius Calderó, Sònia; Bergadà Bertran, Laura; Maiques Carlos, Oscar; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Company of Biologists, 2013)PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. The role of PTEN in carcinogenesis has been validated by knockout mouse models. PTEN heterozygous mice develop neoplasms in multiple ...